VTE Treatment Conventional Approach

Slides:



Advertisements
Similar presentations
Neue Antikoagulantien bei spontaner und Tumor-assoziierter VTE Paul Kyrle Univ. Klinik f. Innere Medizin I AKH/Medizinische Universität Wien.
Advertisements

Extended Anticoagulation in VTE Geoffrey Barnes, MD Cardiovascular and Vascular Medicine University of Michigan, USA 1 st Qatar Conference on Safe Anticoagulation.
Anticoagulation and Thrombosis Management
TREATMENT OF ACUTE PULMONARY THROMBOEMB0LISM SEYED REZA SEYEDI.MD.
Review on NOACs Studies DR. KOUROSH SADEGHI TEHRAN UNIVERSITY OF MEDICAL SCIENCES.
NOACs for Cancer-Associated Thrombosis:
Extended Treatment of VTE: Who is the Right Candidate?
NOACs In Long-term VTE Treatment: A State Of The Art Review
Post-autologous Transplant Therapy for Hodgkin Lymphoma
Rome, 15th December 2015 Valeria Maida Medical Affairs
Long-Term Treatment of VTE: Case Studies
US Guidelines US Guidelines Low-risk Patients.
When Is Adding Aspirin to NOACs Worth the Risk?
Thrombosis, Cancer, and NOACs
Access to NOAC Therapy:
NOACs in Clinical Practice: Are They All the Same?
Emergency Management of NOAC Bleeding
Advances in Coronary Artery Disease: Moving Beyond Antiplatelet Therapy.
Unmet Needs in the Secondary Prevention in ACS
Up to Date on Which NOAC for Which Patient
Clinical Presentations of VTEa,b NOACs VTE Acute Treatment Trials.
Oral Anticoagulants in AFa,b A Brief History.
Surveying the Safety of NOACs in the Real World
Selecting NOACs for High-Risk Patients
A Case Challenge: Anticoagulant Choices for Acute PE
NOAC Use in AF: REAL-WORLD Studies WITH REAL RESULTS
New Oral Anticoagulants and VTE Management
Real-World Safety of NOACs: What Do We Know Today?
Efficacy and Safety of Edoxaban in Patients With AF and HF
Access to NOAC Therapy:
Antithrombotic Protection in CAD and HF
Adherence in SPAF: Measures to Improve Care
What Anticoagulant Registries Are Revealing
Learning Objectives Classification of VTE Goals of VTE Treatment.
A Better Solution For Cancer Patients With VTE?
VTE in Cancer.
Reversal Strategies for VKA: Truths and Misconceptions
Oral Anticoagulation in AF
Forest plot of the HRs for DOACs vs warfarin for (A) new or recurrent VTE and (B) major bleeding based on the published subanalyses of the patients with.
Real-World Evidence in VTE
Dos and Don’ts for High-Risk Elderly Patients With AF
Extending Treatment for Thrombosis: What’s the Right Choice?
Practical Considerations to Extend Treatment for VTE
Advancing the Treatment of IBD With Biologics
Extraordinary Cases of VTE Prevention in Patients With Cancer
Treatment of Thromboembolic Disease The Need for Multiple Perspectives
Anticoagulation and Thrombosis Management
Trials and Tribulations in VTE: How Do Real-World Data Fit In?
Long-Term Treatment of VTE: Case Studies
A Time for Change for Managing Patients With VTE Who Have Cancer
What You Didn't Know About AF and Renal Dysfunction
Cancer-Associated Thrombosis
New European Anticoagulant Approvals Will They Affect Practical Guidance?
Managing Pulmonary Embolism Posthospital Discharge
Practical Guidance on the Management of Pan-Negative NSCLC
NOAC Studies in VTE AF Studies Superior Outcomes.
Proteasome Inhibitors and Patients
Extraordinary Cases in VTE
How I treat cancer-associated venous thromboembolism
Program Goals Background: Anticoagulation in Patients With VTE.
An Unmet Need.
Disease Burden of VTE Phases of VTE Treatment.
5 Good Minutes on Atrial Fibrillation-related Stroke
Peanut Allergy Immunotherapy
At the Crossroads of Coagulation
VTE Treatment and Secondary Prevention VTE Treatment Trials Initial Dosing.
Treatment Advances for RA
Treatment algorithm. Treatment algorithm. (A) Suggested treatment algorithm for symptomatic and incidental DVT or PE in cancer patients. (B) Suggested.
Antithrombotic Therapy in AF Patients Undergoing PCI
Can the Dual vs Triple Therapy Controversy in Patients With AF Undergoing PCI Be Put to Rest?
Presentation transcript:

VTE Treatment Conventional Approach

Advantages of NOACs Over VKA

VTE Treatment New Oral Single-Drug Approach

NOAC Options for VTE

Phases of VTE Treatment

Unprovoked VTE Treatment Single-Drug Approach

Risk of VTE Recurrence

Extended Therapy

EINSTEIN-PE Efficacy and Safety Outcomes

Provoked VTE Treatment Single-Drug Approach

Apixaban, Dabigatran, and Edoxaban VTE Treatment Trials Efficacy and Safety Outcomes

Factors that Predict High Risk of Recurrence

EINSTEIN-EXT Efficacy and Safety Outcomes

AMPLIFY-EXT Efficacy and Safety Outcomes

EINSTEIN-CHOICE

Abbreviations

References

References (cont)

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.